Replies to post #181464 on Biotech Values

[poorgradstudent]

I have my doubts about that - this stuff is viewed as cutting-edge, and hospitals are likely reluctant to give it up even if it can be done more cost-effectively elsewhere.

I guess we will find out.

I think there are some cases, such as during surgery, where having an in-house team to do rapid staining of sections to gauge margins is worth the expense. But I don't see time as the issue in these DNA diagnostic tests. Over here, I think the infrastructure we have to do these things is more a turf war than a real cost-efficiency calculation.

Agree with your view on sequencing. Eventually it's going to be a routine work-up for all diseases.

[oldberkeley]

I'd like to ask you and PGS a very basic question that exposes my ignorance about the subject; I think that I know the answer, but since it concerns a family member I want to be certain.

Is it true that in order to produce any actionable genomic information, they must have an actual tissue sample?

If a solid tumor is located in the brainstem where the biopsy risk/reward is poor, FMI can't really help?